This phase III trial is comparing the effectiveness of two chemotherapy drugs, given in combination with a targeted therapy in patients with advanced colorectal cancer.
This trial is treating patients with colorectal cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Randomized, Multicenter, Parallel-group, Phase III Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer
Isofol Medical AB
Eligible patients will be randomised to receive ARFOX (Arfolitixorin and 5-FU and Oxaliplatin) and Bevacizumab (Group A) OR mFOLFOX-6 (Leucovorin and 5-FU and Oxaliplatin) and Bevacizumab (Group B).
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More